Archives: ClinicianPOV

IL-23 Inhibitors to Improve Quality of Life in Patients With Psoriasis

The management of psoriasis revolves around injectable biologics that target T helper 17 cells-derived proinflammatory cytokines responsible for the pathogenesis of the disease. IL-23 inhibitors are injected every 8 to 12 weeks, allowing patients to have a better quality of life. Dr Joel M. Gelfand, the director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania Perelman School of Medicine in Philadelphia, discusses how IL-23 inhibitors filled a gap in care for patients with psoriasis.

Next clinicianpov in Clinician POV